Arvinas, Inc. (ARVN) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Arvinas reported revenue of $262.6M, down 0.3% from $263.4M the year before. Net income was -$80.8M (a -30.8% net margin), or -$1.14 per diluted share. Operating margin was -45.1%. Operating activities generated -$273.8M of cash, leaving -$275.7M of free cash flow. At fiscal year end, Arvinas held $717.9M in total assets against $284.0M in total liabilities, including $142.9M of cash and equivalents.
Open the full interactive Arvinas financials → Quarterly statements, key ratios, valuation history and price charts.
Arvinas Key Stats
| Share Price | $6.84 |
|---|---|
| Market Cap | $449.4M |
| Revenue YoY Growth | -0.3% |
| 52-Week Range | $6.84 – $13.83 |
| Shares Outstanding | 64.8 million (basic, 2026 Q2) |
Arvinas Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $21.8M | $46.7M | $131.4M | $78.5M | $263.4M | $262.6M |
| Operating Income | -$124.9M | -$195.3M | -$263.2M | -$401.5M | -$250.2M | -$118.5M |
| Pre-Tax Income | -$119.3M | -$191.0M | -$251.0M | -$363.9M | -$198.3M | -$80.5M |
| Income Tax | $0 | $0 | $20.9M | $900,000 | $600,000 | $300,000 |
| Net Income | -$119.3M | -$191.0M | -$282.5M | -$367.3M | -$198.9M | -$80.8M |
| Diluted EPS | -$3.02 | -$3.82 | -$5.31 | -$6.62 | -$2.77 | -$1.14 |
Arvinas Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $41.9M | $9.5M | $15.6M | $249.7M |
| Net Income | -$35.1M | -$67.4M | -$57.6M | $169.4M |
| Diluted EPS | -$0.48 | -$0.95 | -$0.90 | $2.58 |
Arvinas Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $588.4M | $108.3M | $81.3M | $311.7M | $100.5M | $142.9M |
| Current Assets | $703.1M | $1.55B | $1.24B | $1.28B | $1.07B | $700.7M |
| Total Assets | $717.4M | $1.58B | $1.27B | $1.30B | $1.09B | $717.9M |
| Current Liabilities | $49.1M | $261.7M | $295.1M | $257.1M | $229.8M | $142.5M |
| Total Long-Term Debt | $2.0M | $1.0M | $1.0M | $1.0M | $800,000 | $600,000 |
| Total Liabilities | $75.1M | $799.9M | $703.9M | $644.6M | $529.7M | $284.0M |
| Shareholders' Equity | $642.3M | $781.7M | $564.9M | $660.0M | $561.7M | $433.9M |
Arvinas Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$89.8M | $559.4M | -$273.5M | -$347.8M | -$259.3M | -$273.8M |
| Cash From Investing | $164.3M | -$1.31B | $242.8M | $203.5M | $34.7M | $407.6M |
| Cash From Financing | $504.7M | $278.6M | $4.7M | $374.7M | $7.9M | -$91.4M |
| Free Cash Flow | -$96.2M | $554.7M | -$280.3M | -$350.7M | -$261.1M | -$275.7M |
Figures from Arvinas' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Arvinas financials page for every line item.
Arvinas Company Profile
| Ticker | ARVN |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | New Haven, Connecticut |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Accelerated filer |
| SEC CIK | 0001655759 |
Frequently Asked Questions
What was Arvinas' revenue in fiscal 2025?
Arvinas (ARVN) reported revenue of $262.6M for fiscal 2025.
What is Arvinas' annual revenue history?
Arvinas' annual revenue by fiscal year: 2020: $21.8M; 2021: $46.7M; 2022: $131.4M; 2023: $78.5M; 2024: $263.4M; 2025: $262.6M.
What was Arvinas' net income in fiscal 2025?
Arvinas reported net income of -$80.8M for fiscal 2025.
What was Arvinas' earnings per share (EPS) in fiscal 2025?
Arvinas' diluted EPS was -$1.14 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Arvinas generate in fiscal 2025?
Arvinas generated -$275.7M of free cash flow in fiscal 2025.
What was Arvinas' revenue last quarter?
In its most recent reported quarter (2026 Q2), Arvinas reported revenue of $249.7M.
How much debt does Arvinas have?
Arvinas reported $600,000 of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Arvinas are outstanding?
Arvinas reported a weighted average of 64.8 million basic shares outstanding in 2026 Q2.
What is Arvinas' market cap?
Based on its latest closing price, Arvinas (ARVN) has a market capitalization of about $449.4M.
When does Arvinas' fiscal year end?
Arvinas' fiscal year end, as registered with the SEC, is December 31.
Where is Arvinas headquartered?
Arvinas lists its business address in New Haven, Connecticut in its SEC filings.